28018523|t|Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC)
28018523|a|Stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) is considered standard of care in the medically inoperable patient population. Multiple methods of SBRT delivery exist including fiducial -based tumor tracking, which allows for smaller treatment margins and avoidance of patient immobilization devices. We explore the long-term clinical outcomes of this novel fiducial -based SBRT method. In this single institutional retrospective review, we detail the outcomes of medically inoperable pathologically confirmed stage I NSCLC. Patients were treated with the Cyberknife SBRT system using a planning target volume (PTV) defined as a 5-mm expansion from gross tumor volume (GTV) without creation of an internal target volume (ITV). Dose was delivered in three or five equal fractions of 10 to 20 Gy. Pretreatment and posttreatment pulmonary function test (PFT) changes and evidence of late radiological rib fractures were analyzed for the majority of patients. Actuarial local control, locoregional control, distant control, and overall survival were calculated using the Kaplan-Meier method. Sixty-one patients with a median age of 75 years were available for analysis. The majority (80 %) of patients were deemed to be medically inoperable due to underlying pulmonary dysfunction. Eleven patients (18 %) developed symptomatic pneumothoraces secondary to fiducial placement under CT guidance, which precipitously dropped to 0 % following transition to bronchoscopic fiducial placement. The 2-year rib fracture risk was 21.4 % with a median time to rib fracture of 2.9 years. PFTs averaged over all patients and parameters demonstrated small absolute declines, 5.7 % averaged PFT decline, at approximately 1 year of follow-up, but only the diffusing capacity of lung for carbon monoxide (DLCO) demonstrated a statistically significant decline (10.29 vs. 9.01 mL/min/mmHg, p = 0.01). Five-year local control, locoregional control, and overall surviva l were 87.6, 71.8, and 39.3 %, respectively. Despite reduced treatment margins and lack of patient immobilization, SBRT with fiducial -based tumor tracking achieves clinically comparable long-term outcomes to other linac -based SBRT approaches.
28018523	0	9	Long-term	T079	C0443252
28018523	10	18	outcomes	T080	C0085415
28018523	22	57	stereotactic body radiation therapy	T061	C3896609
28018523	59	63	SBRT	T061	C3896609
28018523	70	78	fiducial	T074	C2826325
28018523	79	87	tracking	T082	C0546881
28018523	92	102	inoperable	T080	C0205187
28018523	103	137	stage I non-small cell lung cancer	T191	C0278504
28018523	139	144	NSCLC	T191	C0278504
28018523	146	181	Stereotactic body radiation therapy	T061	C3896609
28018523	183	187	SBRT	T061	C3896609
28018523	193	227	stage I non-small cell lung cancer	T191	C0278504
28018523	229	234	NSCLC	T191	C0278504
28018523	250	266	standard of care	T061	C2936643
28018523	274	283	medically	T169	C0205476
28018523	284	294	inoperable	T080	C0205187
28018523	295	302	patient	T101	C0030705
28018523	303	313	population	T098	C1257890
28018523	315	331	Multiple methods	T061	C0087111
28018523	335	339	SBRT	T061	C3896609
28018523	340	348	delivery	T058	C0011211
28018523	365	373	fiducial	T074	C2826325
28018523	381	386	tumor	T191	C0027651
28018523	387	395	tracking	T082	C0546881
28018523	414	421	smaller	T080	C0547044
28018523	422	439	treatment margins	T023	C0229985
28018523	457	487	patient immobilization devices	T061	C0035260
28018523	504	513	long-term	T079	C0443252
28018523	514	531	clinical outcomes	T033	C0243095
28018523	540	545	novel	T080	C0205314
28018523	546	554	fiducial	T074	C2826325
28018523	562	573	SBRT method	T061	C3896609
28018523	583	603	single institutional	T073,T093	C1266869
28018523	604	617	retrospective	T080	C1514923
28018523	618	624	review	T169	C0699752
28018523	640	648	outcomes	T169	C1274040
28018523	652	661	medically	T169	C0205476
28018523	662	672	inoperable	T080	C0205187
28018523	673	687	pathologically	T169	C1521733
28018523	688	697	confirmed	T033	C0750484
28018523	698	711	stage I NSCLC	T191	C0278504
28018523	713	721	Patients	T101	C0030705
28018523	727	739	treated with	T061	C0332293
28018523	744	754	Cyberknife	T074	C1300683
28018523	755	766	SBRT system	T061	C3896609
28018523	775	797	planning target volume	T081	C0454199
28018523	799	802	PTV	T081	C0454199
28018523	822	831	expansion	T082	C0205229
28018523	837	855	gross tumor volume	T081	C0475645
28018523	857	860	GTV	T081	C0475645
28018523	862	869	without	T080	C0332288
28018523	870	878	creation	T052	C1706214
28018523	885	907	internal target volume	T081	C0392762
28018523	909	912	ITV	T081	C0392762
28018523	915	919	Dose	T081	C0178602
28018523	924	933	delivered	T169	C1705822
28018523	957	966	fractions	T081	C1264633
28018523	983	995	Pretreatment	T052	C3539076
28018523	1000	1013	posttreatment	T079	C2709088
28018523	1014	1037	pulmonary function test	T060	C0024119
28018523	1039	1042	PFT	T060	C0024119
28018523	1044	1051	changes	T081	C0443172
28018523	1056	1067	evidence of	T169	C0332120
28018523	1068	1072	late	T079	C0205087
28018523	1073	1085	radiological	T060	C0043299
28018523	1086	1099	rib fractures	T037	C0035522
28018523	1122	1130	majority	T054	C0680220
28018523	1134	1142	patients	T101	C0030705
28018523	1212	1219	overall	T080	C1561607
28018523	1220	1228	survival	T169	C0220921
28018523	1255	1274	Kaplan-Meier method	T081	C1720943
28018523	1286	1294	patients	T101	C0030705
28018523	1302	1308	median	T081	C0876920
28018523	1309	1312	age	T032	C0001779
28018523	1344	1352	analysis	T062	C0936012
28018523	1358	1366	majority	T054	C0680220
28018523	1377	1385	patients	T101	C0030705
28018523	1404	1413	medically	T169	C0205476
28018523	1414	1424	inoperable	T080	C0205187
28018523	1443	1452	pulmonary	T023	C0024109
28018523	1453	1464	dysfunction	T046	C0277785
28018523	1473	1481	patients	T101	C0030705
28018523	1511	1535	pneumothoraces secondary	T047	C2062858
28018523	1539	1557	fiducial placement	T061	C3888577
28018523	1564	1575	CT guidance	T060	C0475322
28018523	1583	1604	precipitously dropped	T033	C0243095
28018523	1622	1632	transition	T052	C2700061
28018523	1636	1649	bronchoscopic	T074	C0179432
28018523	1650	1668	fiducial placement	T061	C3888577
28018523	1681	1693	rib fracture	T037	C0035522
28018523	1694	1698	risk	T033	C0582456
28018523	1717	1723	median	T081	C0876920
28018523	1732	1744	rib fracture	T037	C0035522
28018523	1759	1763	PFTs	T060	C0024119
28018523	1782	1790	patients	T101	C0030705
28018523	1795	1805	parameters	T077	C0549193
28018523	1819	1824	small	T081	C0700321
28018523	1825	1833	absolute	T080	C0205344
28018523	1834	1842	declines	T081	C0547047
28018523	1859	1862	PFT	T060	C0024119
28018523	1863	1870	decline	T081	C0547047
28018523	1899	1908	follow-up	T058	C1522577
28018523	1923	1969	diffusing capacity of lung for carbon monoxide	T033	C2143174
28018523	1971	1975	DLCO	T033	C2143174
28018523	1992	2017	statistically significant	T081	C0237881
28018523	2018	2025	decline	T081	C0547047
28018523	2117	2124	overall	T080	C1561607
28018523	2125	2132	surviva	T169	C0220921
28018523	2186	2193	reduced	T080	C0392756
28018523	2194	2211	treatment margins	T023	C0229985
28018523	2216	2220	lack	T080	C0332268
28018523	2224	2231	patient	T101	C0030705
28018523	2232	2246	immobilization	T061	C0020944
28018523	2248	2252	SBRT	T061	C3896609
28018523	2258	2266	fiducial	T074	C2826325
28018523	2274	2279	tumor	T191	C0027651
28018523	2280	2288	tracking	T082	C0546881
28018523	2320	2329	long-term	T079	C0443252
28018523	2330	2338	outcomes	T169	C1274040
28018523	2348	2353	linac	T074	C0023730
28018523	2361	2376	SBRT approaches	T061	C3896609